Zelboraf Approved for Late-Stage Melanoma

The FDA today approved Zelboraf (vemurafenib) for the treatment of advanced or metastatic melanoma. The drug extends survival for the 50% of melanoma patients whose tumors carry the BRAF mutation.

Click here to read the full story.

Post a Comment

Enter the words shown above Enter the numbers you hear
Refresh Image Audio Help
No comments yet!

The Health News section does not provide medical advice, diagnosis or treatment. See additional information.

Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.